Cohen H, Hunt J B, Dixit M, Kanwar S, Thomas H C
Department of Haematology, St Mary's Hospital Medical School, Imperial College of Science, Technology and Medicine, London.
Br J Haematol. 1993 Nov;85(3):542-5. doi: 10.1111/j.1365-2141.1993.tb03345.x.
We studied extrinsic and intrinsic fibrinolysis in 20 patients with cirrhosis (nine mild/moderate, group 1; 11 severe, group 2) and 19 normal controls to define the role of intrinsic (contact factor medaited) fibrinolysis in cirrhosis. Global plasma fibrinolytic activity (fibrin plate lysis) was similar in all groups. Dextran sulphate activated contact factor mediated fibrinolysis was decreased in group 2 (median 95.2%) compared with group 1 (121.0%) and controls (131.7%). Tissue plasminogen activator antigen (t-PA Ag) levels were increased in group 2 (28.2 ng/ml) compared both with group 1 (8.5 ng/ml) and controls (5.9 ng/ml). Plasma t-PA activity was raised in group 2 (5.50 IU/ml) and group 1 (5.25 IU/ml) versus controls (0.82 IU/ml). Plasminogen activator inhibitor-1 (PAI-1 Ag) levels were raised in group 2 (28.0 IU/ml) versus controls (8.5 IU/ml) but PAI activity was similar in all groups. Factor XII activity was decreased in group 2 (48.76 u/dl), but not group 1, versus controls (89.1 u/dl). Prekallikrein activity was decreased both in group 2 (27.27 u/dl) and group 1 (33.01 u/dl) versus controls (108.59 u/dl) and was lower in group 2 than group 1. C1-esterase inhibitor chromogenic activity was decreased in group 1 (102.30 u/dl) and group 2 (58.76 u/dl) versus controls (116.24 u/dl). The normal global fibrinolytic activity despite increased t-PA activity may be due to a concomitant increase in PAI. The decreased intrinsic fibrinolysis in severe cirrhosis, unaccompanied by a rise in C1-esterase inhibitor, may be explained by the decreased factor XII and prekallikrein activity. These changes are probably due to reduced liver cell mass.
我们研究了20例肝硬化患者(9例轻度/中度,第1组;11例重度,第2组)和19名正常对照者的外源性和内源性纤溶情况,以明确内源性(接触因子介导)纤溶在肝硬化中的作用。所有组的血浆总体纤溶活性(纤维蛋白平板溶解)相似。与第1组(121.0%)和对照组(131.7%)相比,第2组硫酸葡聚糖激活的接触因子介导的纤溶降低(中位数95.2%)。与第1组(8.5 ng/ml)和对照组(5.9 ng/ml)相比,第2组组织型纤溶酶原激活物抗原(t-PA Ag)水平升高(28.2 ng/ml)。与对照组(0.82 IU/ml)相比,第2组(5.50 IU/ml)和第1组(5.25 IU/ml)的血浆t-PA活性升高。与对照组(8.5 IU/ml)相比,第2组纤溶酶原激活物抑制剂-1(PAI-1 Ag)水平升高(28.0 IU/ml),但所有组的PAI活性相似。与对照组(89.1 u/dl)相比,第2组(48.76 u/dl)的因子Ⅻ活性降低,但第1组未降低。与对照组(108.59 u/dl)相比,第2组(27.27 u/dl)和第1组(33.01 u/dl)的前激肽释放酶活性均降低,且第2组低于第1组。与对照组(116.24 u/dl)相比,第1组(102.30 u/dl)和第2组(58.76 u/dl)的C1酯酶抑制剂显色活性降低。尽管t-PA活性增加,但总体纤溶活性正常可能是由于PAI同时增加。重度肝硬化中内源性纤溶降低且C1酯酶抑制剂未升高,可能是由于因子Ⅻ和前激肽释放酶活性降低所致。这些变化可能是由于肝细胞量减少。